Rule 2.7, 3.10.3, 3.10.4, 3.10.5

# Appendix 3B

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12

Name of entity

**Amex Resources Limited** 

ABN

55 089 826 237

We (the entity) give ASX the following information.

#### Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

1 +Class of +securities issued or to be issued

Ordinary shares Unlisted options

2,222,223 shares

- 2 Number of \*securities issued or to be issued (if known) or maximum number which may be issued
- Principal of terms the 3 +securities if options, (eg, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if securities, +convertible the conversion price and dates for conversion)

2,000,000 unlisted options

Shares - fully paid ordinary Unlisted options – 2,000,000 60 month \$0.80 exercise price expiring 30/12/2020

<sup>+</sup> See chapter 19 for defined terms.

4	Do the *securities rank equally in all respects from the date of allotment with an existing *class of quoted *securities?	Shares – Yes Options - unlisted
	<ul> <li>If the additional securities do not rank equally, please state:</li> <li>the date from which they do</li> <li>the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment</li> <li>the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment</li> </ul>	
5	Issue price or consideration	Shares issued at \$0.45 @ Unlisted options - nil consideration
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	Shares issued to raise capital as approved by shareholders at the 16 <sup>th</sup> November 2015 AGM 2,000,000 60 month options issued as a component of the capital raise under rule 7.1
6a	Is the entity an <sup>+</sup> eligible entity that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b – 6h <i>in relation to the</i> <sup>+</sup> <i>securities the</i> <i>subject of this Appendix 3B</i> , and comply with section 6i	yes
6b	The date the security holder resolution under rule 7.1A was passed	16 November 2015
6c	Number of *securities issued without security holder approval under rule 7.1	1,000,000 \$0.80 48 month unlisted options 2,000,000 \$0.80 60 month unlisted options

<sup>+</sup> See chapter 19 for defined terms.

- 6d Number of \*securities issued nil with security holder approval under rule 7.1A
- 6e Number of \*securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)
- 6f Number of securities issued under an exception in rule 7.2
- 6g If securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the issue date and both values. Include the source of the VWAP calculation.
- 6h If securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements
- 6i Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements
- 7 Dates of entering <sup>+</sup>securities into uncertificated holdings or despatch of certificates
- 8 Number and <sup>+</sup>class of all <sup>+</sup>securities quoted on ASX (*including* the securities in section 2 if applicable)

Number	+Class
108,043,080	Fully paid ordinary shares

nil

nil

n/a

5 January 2016

n/a

7.1 – 13,206,462 per annexure A 7.1A – 10,804,308 per annexure A

+ See chapter 19 for defined terms.

9 Number and <sup>+</sup>class of all <sup>+</sup>securities not quoted on ASX (*including* the securities in section 2 if applicable)

Number	+Class
1,750,000	options exercise price
	\$1.02 expiring 21/4/2016
2,000,000	options exercise price
	\$1.30 expiring 4/9/2016
500,000	options exercise price
	\$1.40 expiring 4/6/2016
5,000,000	options exercise price
	\$1.30 expiring 11/9/2016
1,000,000	options exercise price
	\$1.40 expiring 4/5/2017
500,000	options exercise price
	\$1.40 expiring 24/5/2017
500,000	options exercise price
	\$1.40 expiring 22/7/2017
12,000,000	options exercise price
	\$1.10 expiring 9/1/2018
10,000,000	options exercise price
	\$0.80 expiring 17/11/18
2,000,000	options exercise price
	\$0.80 expiring 4/2/2019
3,000,000	options exercise price
	\$0.80 expiring 17/11/19
2,000,000	options exercise price
	\$0.80 expiring 30/12/2020

10 Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

# Part 2 - Bonus issue or pro rata issue


11	Is security holder approval required?	
12	Is the issue renounceable or non- renounceable?	
13	Ratio in which the <sup>+</sup> securities will be offered	
14	<sup>+</sup> Class of <sup>+</sup> securities to which the offer relates	
15	<sup>+</sup> Record date to determine entitlements	
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	

<sup>+</sup> See chapter 19 for defined terms.


- 17 Policy for deciding entitlements in relation to fractions
- 18 Names of countries in which the entity has \*security holders who will not be sent new issue documents

Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.

- 19 Closing date for receipt of acceptances or renunciations
- 20 Names of any underwriters



- 22 Names of any brokers to the issue
- 23 Fee or commission payable to the broker to the issue
- 24 Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of \*security holders
- 25 If the issue is contingent on +security holders' approval, the date of the meeting
- 26 Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled
- 27 If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders
- 28 Date rights trading will begin (if applicable)



+ See chapter 19 for defined terms.

- 29 Date rights trading will end (if applicable)
- 30 How do <sup>+</sup>security holders sell their entitlements *in full* through a broker?
- 31 How do <sup>+</sup>security holders sell part of their entitlements through a broker and accept for the balance?
- 32 How do <sup>+</sup>security holders dispose of their entitlements (except by sale through a broker)?

<sup>+</sup>Despatch date

## Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

- 34 Type of securities (*tick one*)
- (a)

Securities described in Part 1

(b) All other securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

### Entities that have ticked box 34(a)

#### Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

35

If the <sup>+</sup>securities are <sup>+</sup>equity securities, the names of the 20 largest holders of the additional <sup>+</sup>securities, and the number and percentage of additional <sup>+</sup>securities held by those holders

<sup>+</sup> See chapter 19 for defined terms.

		Number	Class
		Number	+Class
	(if issued upon conversion of another security, clearly identify that other security)		
	Example: In the case of restricted securities, end of restriction period		
41	Reason for request for quotation now		
	<ul> <li>If the additional securities do not rank equally, please state:</li> <li>the date from which they do</li> <li>the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment</li> <li>the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment</li> </ul>		
40	Do the <sup>+</sup> securities rank equally in all respects from the date of allotment with an existing <sup>+</sup> class of quoted <sup>+</sup> securities?		
39	Class of <sup>+</sup> securities for which quotation is sought		
38	Number of securities for which <sup>+</sup> quotation is sought		
Entiti	ies that have ticked box 34(b)		
37	A copy of any trust deed for t	he additional <sup>+</sup> secu	ırities
	1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over		
	+securities setting out the nu 1 - 1,000	mber of holders in	the categories

42 Number and <sup>+</sup>class of all <sup>+</sup>securities quoted on ASX (*including* the securities in clause 38)

<sup>+</sup> See chapter 19 for defined terms.

#### Quotation agreement

- <sup>1</sup> <sup>+</sup>Quotation of our additional <sup>+</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>+</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those +securities should not be granted +quotation.
  - An offer of the <sup>+</sup>securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the <sup>+</sup>securities to be quoted under section 1019B of the Corporations Act at the time that we request that the <sup>+</sup>securities be quoted.
- 3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before 'quotation of the 'securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:	G Dunlop	Date:	6/1/2016
-	Company secretary		

Print name: Gary Dunlop.....

== == == == ==

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3B – Annexure 1

# Calculation of placement capacity under rule 7.1 and rule 7.1A for \*eligible entities

Introduced 01/08/12

## Part 1

Rule 7.1 – Issues exc	ceeding 15% of capital	
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
<i>Insert</i> number of fully paid ordinary securities on issue 12 months before date of issue or agreement to issue	92,340,857	
Add the following:		
<ul> <li>Number of fully paid ordinary securities issued in that 12 month period under an exception in rule 7.2</li> </ul>	100,000 options exercised 4/2/2015 25,000 options exercised 5/3/2015 300,000 options exercised 28/4/2015 1,555,000 options exercised 9/6/2015	
<ul> <li>Number of fully paid ordinary securities issued in that 12 month period with shareholder approval</li> </ul>	1,000,000 issued 4/2/2015 – approved by shareholders 27/11/2014 – resolution four 500,000 issued 25/03/2015 - approved by shareholders 16/11/2015 – resolution three	
	10,000,000 issued 17/11/2015 - approved by shareholders 16/11/2015 - resolution seven	
<ul> <li>Number of partly paid ordinary securities that became fully paid in that 12 month period</li> </ul>	2,222,223 issued 5/1/2016 - approved by shareholders 16/11/2015 – resolution four	
<ul> <li>Note:</li> <li>Include only ordinary securities here – other classes of equity securities cannot be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
<b>Subtract</b> the number of fully paid ordinary securities cancelled during that 12 month	nil	

<sup>+</sup> See chapter 19 for defined terms.

period	
"A"	108,043,080

Step 2: Calculate 15% of "A"	
"B"	0.15
	[Note: this value cannot be changed]
<i>Multiply</i> "A" by 0.15	16,206,462
Step 3: Calculate "C", the amount of 7.1 that has already been used	of placement capacity under rule
<i>Insert</i> number of equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:	1,000,000 unlisted options \$0.80 exercise price 48 month expiry date issued 17/11/2015
<ul><li>Under an exception in rule 7.2</li><li>Under rule 7.1A</li></ul>	2,000,000 unlisted options \$0.80 exercise price 60 month expiry date issued 30/12/2015
<ul> <li>With security holder approval under rule 7.1 or rule 7.4</li> </ul>	
Mater	

## Note:

•	This applies to equity securities, unless
	specifically excluded – not just ordinary
	securities
	lashing have (if any liss his ) the

Include here (if applicable ) the securities the subject of the Appendix 3B to which this form is annexed
 It may be useful to set out issues of

 It may be useful to set out issues of securities on different dates as separate line items

# "**C**" 3,000,000

# Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1

"A" x 0.15	16,206,462
Note: number must be same as shown in Step 2	
Subtract "C"	3,000,000
Note: number must be same as shown in Step 3	

<sup>+</sup> See chapter 19 for defined terms.

<i>Total</i> ["A" x 0.15] – "C"	13 ,206,462
	[Note: this is the remaining placement capacity under rule 7.1]

## Part 2

Rule 7.1A – Additional placement capacity for eligible entities		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A"	108,043,080	
Note: number must be same as shown in Step 1 of Part 1		
Step 2: Calculate 10% of "A"		
"D"	0.10	
	Note: this value cannot be changed	
<i>Multiply</i> "A" by 0.10	10,804,308	
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used		
<i>Insert</i> number of equity securities issued or agreed to be issued in that 12 month period under rule 7.1A		
<ul> <li>Notes:</li> <li>This applies to equity securities – not just ordinary securities</li> <li>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</li> <li>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
"E"	nil	

<sup>+</sup> See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A		
"A" x 0.10	10,804,308	
Note: number must be same as shown in Step 2		
Subtract "E"	0	
Note: number must be same as shown in Step 3		
<i>Total</i> ["A" x 0.10] – "E"	10,804,308	
	Note: this is the remaining placement capacity under rule 7.1A	

<sup>+</sup> See chapter 19 for defined terms.